The agreement dictates that the two firms will research and develop ReForm Biologics' excipients for pharmaceutical use, with MilliporeSigma funding the effort and taking responsibility for global marketing, manufacturing, and sale of the excipients to its customers. ReForm Biologics will receive revenues from MilliporeSigma for sublicensing ReForm Biologics' technology, it said.